Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutation: an ambispective cohort study.
About 10% of non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor...
Read More